SentiVeillance Server is a ready-to-use solution that integrates with surveillance video management systems (VMS). Based on the company’s deep neural network technology for facial recognition from surveillance camera video, SentiVeillance Server enhances VMS with advanced capabilities, such as the ability to quickly and accurately recognize faces in video streams and trigger analytical event notifications whenever an authorized, unauthorized or unknown person is detected. This greatly improves the workflow of VMS operators, allowing them to quickly react to changing situations and to easily view video of past events and filter them by gender, age or person ID.
“SentiVeillance Server enables advanced analytics in many video management systems where it was too complex or too expensive before,” said Aurimas Juska, Neurotechnology software development team lead. “Users can benefit from an enhanced surveillance system with only a small amount of configuration and no need for programming.”
SentiVeillance Server supports most popular video management systems: Milestone XProtect VMS and Luxriot Evo, Evo S and Evo Global. SentiVeillance Server can process up to 10 video streams from multiple video management systems, all in real time.
SentiVeillance Server includes Neurotechnology’s latest deep neural-network-based facial detection and recognition algorithm which significantly improves identification accuracy and speed. The algorithm is based on more than 13 years of development and research and has been tested in the NIST Face Recognition Vendor Test (FRVT) Ongoing. It is also included in other Neurotechnology products, such as the VeriLook and MegaMatcher software development kits (SDK), which have millions of deployments worldwide.
Neurotechnology also offers the SentiVeillance SDK for development of solutions using facial identification and object recognition from surveillance video.
SentiVeillance Server and the SDKs noted above are all available through Neurotechnology or from distributors worldwide.
For more information and trial version, go to: www.neurotechnology.com.
